March 30, 2022
San Diego, Calif. – March 30, 2022 – Arima Genomics, Inc., the leader in 3D genomics, today announced the appointment of Chris Roberts to the newly created position of Senior Vice President of Corporate Strategy.
Chris brings a wealth of life sciences leadership experience across both research-oriented and clinically focused companies. Most recently he was Vice President, Corporate Initiatives for Veracyte, Inc., responsible for leading the commercial marketing, product strategy, strategic reimbursement, and field scientific-support organizations for the urology division. He previously also held senior leadership roles with HTG Molecular Diagnostics, Caris Life Sciences, and marketing roles with Ventana Medical Systems and Pall Biosciences. He holds a BS in Chemical Engineering from the Georgia Institute of Technology and an MBA from Duke University.
“I see great potential in Arima Genomics’ technology for preserving the three-dimensional organization of the genome in elucidating the functional drivers of an individual patient’s journey,” said Chris Roberts, Senior Vice President of Corporate Strategy at Arima Genomics. “The field of genomics is expanding rapidly and shows promise in a variety of clinically-relevant applications. I look forward to joining the Arima Genomics team in realizing the full potential of its product portfolio and expanding its global base of customers.”
As Senior Vice President of Corporate Strategy, Chris will develop a strategic plan for the company, helping to bring decisive focus and prioritization to the company’s 3D genomics portfolio expansion, entrée into the clinical market, and customer acquisition activities. These efforts will be critical as the organization scales to enhance its bioinformatics offerings and develop new solutions that serve a broad spectrum of scientific, translational medicine, and clinical applications.
“I am thrilled to welcome Chris to our team. His broad experience and contacts across the life science industry will help us accelerate supporting our customers in developing the body of evidence illustrating the importance of genome structure in health and disease,” said Siddarth Selvaraj, Chief Executive Officer of Arima Genomics. “As the importance of genomic structure as a driver of disease becomes better understood, he will play a critical role in helping develop markets across emerging research, translational, and clinical applications.”
About Arima Genomics
Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.
For general inquiries
Pamela Bentley Mills, PhD